Table 3.
Referral reason, n (%) | Prepandemic (Jan 1–Feb 19)a |
P for difference | Pandemic (Feb 26–Apr 22) |
P for difference | Postpandemic (Apr 29–Jul 8)b |
P value a vs. b |
---|---|---|---|---|---|---|
Referrals (n = 384) | Referrals (n = 193) | Referrals (n = 450) | ||||
Unintentional weight loss | 54 (14.06) | 0.024 | 40 (20.73) | <0.001 | 52 (11.56) | 0.129 |
Severe fatigue | 8 (2.08) | 0.004 | 17 (8.81) | 0.052 | 22 (4.89) | 0.118 |
Fever of unknown origin | 20 (5.21) | <0.001 | 28 (14.51) | 0.048 | 46 (10.22) | 0.023 |
Anemia | 83 (21.61) | <0.001 | 14 (7.25) | <0.001 | 65 (14.44) | <0.001 |
Persistent nausea/appetite loss | 9 (2.34) | 0.219 | 10 (5.18) | 0.065 | 7 (1.56) | 0.227 |
Change in bowel habit | 37 (9.64) | 0.088 | 26 (13.47) | 0.030 | 38 (8.44) | 0.255 |
Abdominal pain | 23 (5.99) | 0.212 | 14 (7.25) | 0.113 | 19 (4.22) | 0.221 |
Rectal bleeding/hematochezia | 34 (8.85) | <0.001 | 3 (1.55) | 0.072 | 21 (4.67) | 0.013 |
Dysphagia | 6 (1.56) | 0.098 | 10 (5.18) | 0.190 | 16 (3.56) | 0.106 |
Abnormal laboratory tests | 10 (2.60) | 0.228 | 2 (1.04) | 0.420 | 6 (1.33) | 0.202 |
Lymphadenopathy or palpable lumps | 31 (8.07) | 0.001 | 4 (2.07) | <0.001 | 43 (9.56) | 0.187 |
Lung or mediastinal mass | 8 (2.08) | 0.209 | 1 (0.52) | 0.155 | 14 (3.11) | 0.179 |
Pulmonary infiltrate | 2 (0.52) | 0.460 | 2 (1.04) | 0.326 | 0 (0.00) | 0.312 |
Abdominal mass | 14 (3.65) | 0.102 | 1 (0.52) | 0.038 | 25 (5.56) | 0.164 |
Jaundice | 3 (0.78) | 0.316 | 0 (0.00) | 0.249 | 6 (1.33) | 0.296 |
Ascites | 2 (0.52) | 0.453 | 2 (1.04) | 0.720 | 5 (1.11) | 0.322 |
Pain (other than abdominal) | 20 (5.21) | 0.140 | 6 (3.11) | 0.063 | 29 (6.44) | 0.138 |
Dyspnea | 7 (1.82) | 0.088 | 10 (5.18) | 0.695 | 24 (5.33) | 0.091 |
Peripheral edema | 2 (0.52) | 0.519 | 2 (1.04) | 0.586 | 4 (0.89) | 0.422 |
Pleural effusion | 10 (2.60) | 0.144 | 1 (0.52) | 0.401 | 5 (1.11) | 0.156 |
Hematuria | 1 (0.26) | 0.844 | 0 (0.00) | 0.377 | 3 (0.67) | 0.343 |